ClinicalTrials.gg
RecruitingNCT06084520COMMISSUpdated May 10, 2024

Translation and Validation of the COMM and ASI-SR

An observational study in Opioid Use, Opioid Use Disorder and Alcohol Use Disorder, sponsored by Uppsala University. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by Uppsala University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Opioid-Related Disorders with a site in Sweden — 2 open to participants now, 4 under way, none of them phase 3. Opioid-Related Disorders · Sweden.

Started
2023
with 3 others
Observational
7 of 13
2 open now
Registered
13th of 13
by date
Lead sponsor
3 of 13
Uppsala University

Among the 13 studies in Opioid-Related Disorders with a site in Sweden, this one is one of 4 that started in 2023, is one of 7 observational ones, and was the 13th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

2 of the 13 studies in Opioid-Related Disorders with a site in Sweden are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Opioid-Related Disorders with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this observational study is to translate the COMM (Current opinion misuse measure) form and validate it using the ASI-SR (Addiction severity score-self report)in a Swedish population of pain patients treated with opioids. The secondary aim is to investigate acceptability of the instrument in a Swedish population of pain patients with long-term opioid treatment (LOT).

The tertiary aim is to investigate the prevalence of alcohol and illicit substance use in a Swedish population of pain patients with LOT.

Read the detailed description

There is no validated instrument for the assessment of early detection of substance use disorder development in swedish language.

In order to address this gap, investigators plan to translate and validate the COMM questionnaire using the ASI-SR in a Swedish population of pain patients undergoing opioid treatment. In addition, study will investigate the prevalence of illicit substance use in this population and compare it to patients who are not receiving opioid treatment. The collection of material (blood) in the Uppsala Biobank for future analysis of neurobiological processes during long-term pain treatment will be performed.

Phase 1:

Translation of the instrument takes place according to the "Patient-Reported Outcome (PRO) Consortium translation process guidelines"and according to guidelines from the company MAPI ResearchTrust, which owns the rights to use of the instrument.

Phase 2: The subsequent phase entails validating the COMM instrument against the ASI-SR in a Swedish sample of patients experiencing long-term pain, in accordance with the "Cosmin guidelines" [40], and involves the following procedures. Firstly, the reliability of the COMM instrument by examining internal consistency, test-retest consistency, standard error of measurement (SEM), and conducting factor analysis with rotation in a Swedish population of patients with long-term pain andlong-term opioid treatment (LOT)will be assessed. Secondly, validity of the COMM instrument with regard to comprehensiveness, scope, user-friendliness, and predictability within this particular population will be investigated. Furthermore, investigators will assess the acceptability of the instrument among the study population. Finally, exploration of the prevalence of substance use alongside LOT in pain patients and compare it with pain patients who do not receive opioid treatment will be performed. Inclusion goal is to recruit 200 research subjects from various healthcare settings, including primary care, specialized pain care, other specialized care (e.g., Endometriosis Center), and addiction care (addiction medicine program for pain patients) for the test group. Additionally, 200 individuals are planned to be recruited from pain centers and primary care for the control group to measure prevalence rates. The control group will consist of patients with long-term pain who are not undergoing opioid treatment. Since the study involves two groups of patients with long-term pain (with and without opioid treatment), research group will inquire separately if participants are willing to provide blood samples for biomarker analysis of pain (O-link panel) and genetic analysis, which will be stored in the biobank for future research on the effects of opioids.

Validation will be conducted using the results of drug and alcohol analysis from salivatests and blood. Each category, as identified by the original COMMinstrument, will be evaluated against the following instruments:

  1. Symptoms and signs of drug abuse (question 1) - AUDIT, DUDIT, ASI-SR, drug and alcohol test
  2. Emotional and psychiatric problems (questions 2, 5, 7, 8, 13) - ASI-SR, GAD-7, PHQ9
  3. Visitor characteristics/patterns (questions 3, 12, 17) - medical record data
  4. Occurrence of untrue statements (doubt/lie/untruth) and drug use (questions 4, 6, 9, 10, 11) - medical record data, drug and alcohol tests
  5. Medication use and deviation from prescription (non-compliance) (questions 14, 15, 16) - medical record data, occurrence of overprescription. Pain-related questions will be assessed using the BPI-SF.

In addition, research subjects will also be asked if they would like to be interviewed by a researcher in connection with their consent. Thirty of the initial research subjects who respond positively will undergo a semi-structured interview, where ease of use will be examined using the "think aloud" method. This involves asking subjects about their thoughts on the forms, including their understanding of the questions, language choices, and any possible negative associations. The interviews will then be reviewed using qualitative content analysis.

Moreover, an extensive assessment will be undertaken, involving the input of 10 esteemed professionals in Sweden who specialize in various fields related to this subject matter, such as pain doctors, addiction medicine doctors, psychologists, behavioral scientists, and others. These experts will be approached to provide their valuable insights by responding to a set of carefully devised questions concerning the evaluation of content validity. Their estimations will serve as the fundamental basis for calculating the Content Validity Index (CVI).

In order to collect and analyze the health data, information from medical records, relevant forms, and laboratory responses are compiled into a study database and then transferred to a statistics program. To ensure internal consistency and reliability, Cronbach's alpha is used, with the expectation that it will be higher than 0.70 at a significance level of p\<0.05. Additionally, the agreement between the two test occasions of COMM is assessed using the intraclass correlation coefficient (ICC). The ICC is classified as satisfactory if below 0.40, good if between 0.40-0.59, and excellent if between 0.60-0.70. The correlation between the results of COMM and the ASI-SR is examined using both the Pearson and Spearman correlation coefficients, which are calculated for the respective clusters of questions in the form. Furthermore, confirmatory factor analysis with rotation is employed to investigate the relationship between different clusters or dimensions of questions that can be identified for correlation purposes. The discriminant validity of ASI-SR composite scores and external validity measures are determined by calculating the intercorrelation matrix between COMM groups of questions, ASI-SR composite scores, and external validation measures. The minimum requirement for correlation is set at >0.40. Statistical processing is conducted using SPSS, SAP, and Amos programs. It should be noted that the qualitative aspect of the study is not covered by the statistical plan. In terms of prevalence estimation, both the test group and the control group will be described using descriptive statistics. The occurrence of addictive drugs, non-prescribed drugs, and measures of alcohol use (PETh) during the last three weeks in both groups will be compared using a chi-square test. Odds analysis will be performed to assess secondary use of illegal substances, parallel dependence on other substances, and drugs and alcohol during the length of the study.

03

Conditions studied

  • Opioid Use
  • Opioid Use Disorder
  • Alcohol Use Disorder
  • Pain, Chronic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Chronic pain patients (18-75 years old) within Uppsala County treated both in Primary care, Secondary care ( Endometrios center) and Tertiary care ( Pain and Addiction clinic)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Intervention group:

  • Patients with long-term, non-cancer-related pain (>3 months) at least 3 days a week
  • opioid treatment for at least 1 month during last 6 months
  • age 18-75 years
  • fluent in spoken and written Swedish.

Control group:

  • Patients with long-term, non-cancer-related pain (>3 months) at least 3 days a week
  • no opioid treatment at inclusion and during last 3 months
  • age 18-75 years
  • fluent in spoken and written Swedish

Exclusion criteria

Exclusion Criteria:

  • ongoing diseases or conditions that prevents the patient from completing to the study according to the doctor's assessment
  • serious cognitive disorder that makes answering the questions impossible. - - ongoing or treated cancer in the last 10 years
  • Insufficient knowledge of Swedish
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Test group - patients with chronic pain treated with opioids

    Patients with long-term, non-cancer-related pain (\>3 months) at least 3 days a week, age 18-75 years, who have been treated with opioids for at least 1 month and who can speak, read and write in Swedish, recruited within Uppsala County Primary, Secondary and Tertiary Care.

    Diagnostic Test: Current Opioid Misuse Measure (COMM)-SWE · Diagnostic Test: Oral fluid drug test · Diagnostic Test: PETh · Diagnostic Test: ASI-SR · Diagnostic Test: AUDIT · Diagnostic Test: DUDIT · Diagnostic Test: Brief Pain Inventory - BPI · Diagnostic Test: Patient Global Impression of Change PGIC · Diagnostic Test: GAD-7 · Diagnostic Test: Patient Health questionnaire (PHQ9) · Diagnostic Test: DBS - cannabis test · Other: Sample of Blood for later DNA and immunological analysis in future studies

  • Control group - patients with chronic pain not-treated with opioids

    Patients with long-term, non-cancer-related pain (\>3 months) at least 3 days a week, age 18-75 years, who are not treated with opioids (at inclusion and during the last 3 months) and who can speak, read and write in Swedish, recruited within Uppsala County Primary, Secondary and Tertiary Care.

    Diagnostic Test: Oral fluid drug test · Diagnostic Test: PETh · Diagnostic Test: DBS - cannabis test · Other: Sample of Blood for later DNA and immunological analysis in future studies

Interventions

  • Diagnostic testCurrent Opioid Misuse Measure (COMM)-SWE

    Patients in test group should fulfill the the COMM and the battery of validation forms as well as leave the oral fluid for illicit drugs test and whole blod for phosphatidylethanol test.

  • Diagnostic testOral fluid drug test

    Oral fluid sampling to detect drugs. Analysis with LC-HRMS

  • Diagnostic testPETh

    Alcohol use detection

    Also known as: Phosphatydilethanol in blood

  • Diagnostic testASI-SR

    Cross-validation form

    Also known as: Addiction Severity Score - Short version

  • Diagnostic testAUDIT

    Cross-validation form

    Also known as: Alkohol Use Disorder Identification Test

  • Diagnostic testDUDIT

    Cross-validation form

    Also known as: Drug Use Disorder Identification Test

  • Diagnostic testBrief Pain Inventory - BPI

    Cross-validation form

  • Diagnostic testPatient Global Impression of Change PGIC

    Cross-validation form

  • Diagnostic testGAD-7

    Cross-validation form

    Also known as: Generalized anxiety disorder 7-items scale

  • Diagnostic testPatient Health questionnaire (PHQ9)

    Cross-validation form

  • Diagnostic testDBS - cannabis test

    cross-validation form

  • OtherSample of Blood for later DNA and immunological analysis in future studies

    sample collection for future studies

06

What researchers measure

Primary outcomes

  1. COMM - Current opioid misuse version Swedish version

    COMM is based on 17 questions, all of which are answered on a 5-point Likert scale. As the original COMM instrument has identified 5 categories of questions, each area will be assessed against the following instruments: 1. Symptoms and signs of drug abuse (question 1) - AUDIT, DUDIT, ASI-SR, drug and alcohol test 2. Emotional and psychiatric problems (questions 2,5,7,8,13) - ASI-SR, GAD-7, PHQ9 3. Visitor characteristics/patterns (questions 3,12,17) - medical record data 4. Occurrence of untrue statement (doubt/lie/untruth) and drug use (questions 4,6,9,10,11) - medical record data, drug and alcohol tests

    Time frame: Baseline

Secondary outcomes

  1. ASI-SR Addiction severity index - short release

    This instrument is based on interview questions that are used for addiction monitoring by calculating "composite scores", mathematical score measures that are sensitive to change and that are used for follow-up and research. The scoring measures are produced according to a standardized model from the National Board of Health and Welfare (2017). Each domain is calculated in point measures.

    Time frame: Baseline

  2. COMM - 2nd test

    COMM is based on 17 questions, all of which are answered on a 5-point Likert scale. For retest consistency.

    Time frame: 1 week after baseline

  3. AUDIT Alcohol Use Disorder Identification Test

    Scoring system, (0-40)where increase of the points reflects increased risk of problematic alcohol use.

    Time frame: Baseline

  4. BPI-Brief Pain Inventory - short form

    BPI-SF measures ongoing intensity and impact of pain on different areas of life (eg activity, sleep, well-being). Questions are answered in scale 0-10. From there you can calculate the indexes "Pain Intensity" and "Pain Interference".

    Time frame: Baseline

  5. Patient global impression of change - PGI-C

    7-grade scale (-3-+3)where the lowest points indicate negative and highest points indicate positive change.

    Time frame: Baseline

  6. Drug Use Disorder Identification Test (DUDIT)

    Scoring system,(0-44) where increase of the points reflects increased probability of drug abuse syndrome.

    Time frame: Baseline

  7. Patient Health Questionnaire PHQ9

    Depression Assesment scoring system, (0-15) where \<4 is no need of depression treatment, and \>15 identifies need of pharmacologic or other depression treatment

    Time frame: Baseline

  8. Drug detection test - saliva

    Analysis performs with tandem high-resolution liquid mass spectrometry (LC-HRMS) positive/negative results according to the intern cut-off standard

    Time frame: baseline

  9. PETh - Phosphatidylethanol in blood

    Test monitoring alcohol consumtionduring last 3 weeks monitoring. Results talking: no alcohol use \< 0.05 microg/l , moderate use 0.05-0.30, regular high. amount use \>30microg/l.

    Time frame: baseline

  10. Cannabis in DBS ( Dry blood spott)

    Analysis performs with tandem high-resolution liquid mass spectrometry (LC-HRMS) positive/negative results according to the intern cut-off standard

    Time frame: baseline

  11. Generalized anxiety disorder (GAD-7)[

    7-items scale, Summary score (0-21), where severity of anxiety increase with more points: \<5 no anxiety, 6-10 mild, 11-16 moderate, \<17 severe

    Time frame: baseline

Other outcomes

  1. Descriptive characteristics of the group

    Age, sex, level of education, work status is requested in the survey, duration of treatment and pain condition and number of visits to healthcare in the last six months (specifically acute visits), diagnosis for which the preparation is prescribed, preparation and dose and actual amount prescribed in the last 6 months and any signs of overuse or problematic use For evaluating factor structure principal component analyses (PCA) .

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.

Of 74 non-industry observational studies under Opioid-Related Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 24 months is below that.

Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Oct 16, 2023
StartActual
Dec 1, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06084520
Lead sponsor
Uppsala University
Collaborators
The Kamprad Family Foundation for Entrepreneurship, Research & Charity
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Dec 1, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 10, 2024

Study contacts

Lenka Katila, MD
Contact
lenka.katila@uu.se
+46186113739
Rolf Karlsten, PhD
Contact
rolf.karlsten@uu.se
+46186113518
Rolf Karlsten, PhD
principal investigator · Uppsala University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion